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Background
Cten is a protein located at focal adhesions and has been
reported to be an oncogene in colon, breast, lung and
gastric cancer [1-3]. We have previously shown than
Cten is a target of K-ras in colorectal and pancreatic can-
cer [4]. In this study, we investigated whether two other
proposed mechanisms i.e. EGFR and Stat3 signaling were
involved in regulating Cten expression.
Materials and methods
EGF was used to stimulate the EGFR while the PD153035
to inhibit the EGFR. On the other hand, IL-6 used to sti-
mulate the STAT3 and siRNA for STAT3 was used for
knockdown. The effect was confirmed using Western blot
and QPCR and cell motility was assessed by transwell
chambers.
Results
Initially we manipulated EGFR signaling by (i) stimulation
with EGF and (ii) inhibition by the PD153035 in the color-
ectal cancer cell lines SW620 and C32. In C32, EGF stimu-
lation resulted in up-regulation of Kras and Cten whilst
exposure to PD153035 resulted in down-regulation of both
Kras and Cten. EGFR activation and inhibition was
reflected by, respectively, increased and decreased cell
motility although the effect of EGFR activation was lost by
Cten Knockdown. In SW620, which harbours a KRAS
mutation, modulating EGFR activity in this way had no
effect on either Kras or Cten. Stat3 signaling has also been
reported to positively regulate Cten. We tested this in
SW620 by directly knocking down Stat3 and exposing cells
to interleukin-6 (an activator of Stat3). Stat3 knockdown
resulted in increased Cten whilst Stat3 activation resulted
in downregulation of Cten. Testing for Kras expression
showed that Stat3 was negatively regulating Kras and this
was reflected in the Cten expression. Functional analysis
however showed that inhibition of Stat3 resulted in a
reduction of cell motility in a Kras and Cten-independent
manner.
Conclusions
We conclude that both EGFR signals through Kras
to modulate Cten (and consequently ILK/FAK) and stimu-
lates cell motility. Stat3 however negatively regulates Kras
and consequently Cten although its net effect is to
stimulate motility through an alternative mechanism.
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